U.S. FDA Grants Breakthrough Therapy Designation for Tecvayli plus Darzalex Faspro as a Second Line for Patients with Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/tecvayli-darzalex-faspro-second-line-rrmm)